What makes IGF-1 LR3 different from regular IGF-1?

The LR3 modification (N-terminal Arg-Lys extension and Glu→Arg substitution at position 3) reduces IGF-binding protein (IGFBP) binding by approximately 1000-fold. Native IGF-1 has a plasma half-life of 12–15 minutes because ~98% is IGFBP-bound. IGF-1 LR3 has a half-life of 20–30 hours because it remains receptor-available rather than being sequestered. This makes it dramatically more potent and longer-lasting.

What is the hypoglycemia risk with IGF-1 LR3?

IGF-1 has structural homology with insulin and activates insulin receptors at high concentrations, producing insulin-like effects on glucose uptake. IGF-1 LR3's 20–30 hour half-life means this hypoglycemic risk persists for many hours after injection. Users must eat carbohydrates within 20–30 minutes of injection, carry fast-acting glucose, and never inject fasted without glucose available. Signs of hypoglycemia: shakiness, sweating, confusion, headache — treat immediately.

Is IGF-1 LR3 WADA-banned?

Yes. IGF-1 LR3 is banned by the World Anti-Doping Agency (WADA) and detectable in anti-doping testing. It is not FDA-approved for human use. It is used in cell culture research. For competitive athletes, this compound is absolutely prohibited.

COMPOUND LIBRARY·IGF-1 LR3

COMPOUND PROFILE · PEPPERLEDGER

IGF-1 LR3

Type

Synthetic analog of human IGF-1 with N-terminal Arg-Lys extension and Glu→Arg substitution at position 3

Class

IGF-1 receptor agonist — activates IGF-1R directly, bypassing the GH → IGF-1 liver synthesis step

Administration

Subcutaneous or intramuscular injection

Half-life

~20–30 hours — dramatically longer than native IGF-1 (~12–15 minutes) due to ~1000-fold reduced IGFBP binding

Most studied use

Muscle hypertrophy · Fat loss · Recovery · Often used after or alongside GH secretagogue cycles

Regulatory status

Not FDA-approved for human use · Used in cell culture research · WADA-banned · Research chemical

Human evidence

Very limited — no controlled trials in healthy adults for body composition; primary evidence from GH deficiency research and animal models

Preclinical evidence

Strong — well-characterized IGF-1R mechanism; extensive animal data on muscle hypertrophy and fat loss

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is IGF-1 LR3?

IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 (IGF-1) — the primary downstream mediator of growth hormone's anabolic effects. Where GH secretagogues (CJC-1295, ipamorelin, GHRP-2) work by stimulating your pituitary to release GH, which then signals your liver to produce IGF-1, IGF-1 LR3 skips the entire upstream signaling chain and directly activates IGF-1 receptors throughout the body. The result is potent, direct anabolic signaling — protein synthesis in muscle, fat cell breakdown, connective tissue support — without the intermediary steps.

The LR3 modification makes it dramatically more potent and longer-lasting than native IGF-1. Native IGF-1 has a half-life of roughly 12–15 minutes in plasma because it's rapidly bound by IGF-binding proteins (IGFBPs). The LR3 modification reduces IGFBP binding affinity by approximately 1000-fold, extending the half-life to 20–30 hours.

The risks require honest engagement. IGF-1 promotes cell growth broadly — not selectively in muscle. It stimulates IGF-1 receptors on all tissues, including any cancer cells that express IGF-1R. This is a meaningful concern for anyone with undiagnosed cancer or significant cancer risk. Additional risks: hypoglycemia (IGF-1 has insulin-like effects on glucose), organ growth (heart, liver, kidneys with prolonged use), and acromegalic changes with very long protocols.

How it works

IGF-1 Receptor Activation and mTOR

IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) — a receptor tyrosine kinase expressed in virtually all tissues. IGF-1R activation triggers PI3K/Akt/mTOR signaling (protein synthesis, cell growth, survival) and MAPK/ERK signaling (proliferation, differentiation). In muscle: mTOR activation drives ribosomal protein synthesis and muscle fiber growth; satellite cell proliferation enables true hyperplasia rather than just hypertrophy.

The LR3 Modification — Why It's Different

Approximately 98% of circulating native IGF-1 is IGFBP-bound. The LR3 modification reduces IGFBP binding ~1000-fold — IGF-1 LR3 remains bioavailable in plasma for 20–30 hours rather than minutes. This is the pharmacological basis for its potency.

Hypoglycemia Risk

IGF-1 has structural homology with insulin and activates insulin receptors at high concentrations, producing insulin-like effects on glucose uptake. IGF-1 LR3's long half-life means this hypoglycemic risk is sustained for up to 30 hours after injection. Users must eat carbohydrates within 20–30 minutes of injection and have fast-acting glucose available.

What the research shows

HUMAN AND MECHANISTIC EVIDENCE

STUDYJournal of Molecular Endocrinology · 1992

Novel recombinant fusion protein analogues of IGF-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency

Francis GL, Ross M, Ballard FJ et al.

Showed that IGF-I analogues which bind IGF-binding proteins poorly — Long[Arg3]-IGF-I (LR3) and des(1-3)IGF-I — are markedly more potent than native IGF-I in cells that secrete those binding proteins. The structural foundation for why IGF-1 LR3 outperforms native IGF-1.

View on PubMed →

STUDYBritish Journal of Pharmacology · 2008

Regulation of muscle mass by growth hormone and IGF-I — review

Velloso CP

Review of how GH and IGF-I regulate muscle mass — separating systemic (endocrine) from local (autocrine/paracrine) effects, and noting the limited evidence that supraphysiological systemic GH or IGF-I is anabolic in the skeletal muscle of healthy adults. There are still no direct IGF-1 LR3 human muscle trials.

View on PubMed →

THE CANCER RISK — STATED PLAINLY

IGF-1 promotes cell growth broadly. It does not cause cancer de novo — but it can accelerate the growth of existing cancer cells that express IGF-1R, which virtually all do. Do not use if you have active cancer, are in remission, have a strong family history of hormone-sensitive cancers (breast, prostate, colon), elevated PSA, or are over 60 with high cancer background risk without oncology clearance. This is a mechanistically grounded concern, not theoretical.

WHAT THE RESEARCH SHOWS

✓KNOWN

✓LR3 modification reduces IGFBP binding ~1000-fold, extending half-life to 20–30 hours
✓IGF-1R activation drives mTOR → protein synthesis and satellite cell proliferation
✓Hypoglycemia risk via insulin-like receptor cross-activation — documented
✓Potent anabolic effects confirmed in animal models
✓WADA-banned — detected in anti-doping testing

?UNCERTAIN

?Body composition outcomes in healthy adults — no controlled human trials exist
?Whether IGF-1 LR3 accelerates existing cancer growth in humans at biohacker doses
?Long-term organ growth effects (heart, liver, kidneys) at typical doses
?Optimal dosing, frequency, and cycle length for body composition
?Whether benefits exceed GH secretagogue stack outcomes

What the community reports

—Significant muscle fullness and vascularity increase — often noticeable within days; muscle cells take up more nutrients and glycogen

—Accelerated muscle growth on consistent training — faster hypertrophy than GH secretagogue-only protocols

—Fat loss alongside muscle gain — simultaneous body composition improvement is the primary reported benefit

—Hypoglycemia in hours post-injection — the most consistently noted risk; eating carbohydrates shortly after injection generally avoids it

—Joint and connective tissue improvement — collagen synthesis effects similar to BPC-157

—Duration limitation: most experienced users limit cycles to 4–6 weeks due to receptor desensitization and organ growth concerns

Common misconceptions

"IGF-1 LR3 causes cancer."

REALITY

IGF-1 LR3 does not cause cancer de novo. The concern is that elevated IGF-1 can accelerate growth of existing cancer cells that express IGF-1R. This is a meaningful risk for someone with undiagnosed cancer or significant cancer risk — not a claim that it causes cancer to develop in cancer-free individuals.

"IGF-1 LR3 is just stronger GH."

REALITY

GH works by signaling the liver to produce IGF-1, which then acts systemically. IGF-1 LR3 bypasses this entirely and directly activates IGF-1 receptors throughout the body at supraphysiologic levels for 20–30 hours. Direct receptor activation at this level is categorically different from even the strongest GH secretagogue protocols.

"You can run IGF-1 LR3 indefinitely."

REALITY

Prolonged continuous IGF-1R stimulation drives organ growth — heart, liver, and kidneys can enlarge with chronic supraphysiologic IGF-1 exposure. Short cycles (4–6 weeks) with breaks are standard practice to avoid cumulative organ growth effects. This is one of the features of acromegaly.

INDIRECT IGF-1 ELEVATION — LOWER-RISK ALTERNATIVES

CJC-1295 + Ipamorelin elevate IGF-1 indirectly via GH stimulation — within physiological ranges with a much cleaner safety profile. For most users, optimizing the GH secretagogue stack before considering direct IGF-1R activation is the appropriate progression.

RECONSTITUTION CALCULATOR

Peptide in vial (mg)BAC water (mL)Desired dose (mcg)

EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN

AI RESEARCHER PREVIEW

I want to run IGF-1 LR3 after my CJC + ipamorelin cycle. What should I watch for?

Running IGF-1 LR3 after a GH secretagogue cycle is the standard progression — you've been elevating GH and therefore IGF-1 indirectly; now you're considering direct IGF-1R activation. Here's what matters most. Hypoglycemia is the primary acute risk and the one that catches people off guard most often. IGF-1 LR3's 20–30 hour half-life means the insulin-like effect on glucose uptake persists well after injection — not just in the first hour. Practical protocol: never inject fasted. Eat within 20–30 minutes of injection, carbohydrates specifically. Keep fast-acting glucose available (glucose tablets, juice) for the first 24 hours after each injection, especially in week 1 while you're establishing how your body responds. If you feel shaky, sweaty, or confused after injection — that's hypoglycemia, treat immediately. Dose: start at 20 mcg. Not 50, not 100 — 20. This is a potent compound with a 20–30 hour half-life. The first injection tells you a lot about your individual sensitivity. If 20 mcg is well-tolerated with clear effects in training, you can assess whether 30–50 mcg makes sense. Cycle length: 4–6 weeks maximum. IGF-1R desensitization and organ growth concerns make extended cycles inadvisable. The off-period should be at least as long as the cycle. Cancer risk disclosure: before you start — if there's any personal or family history of hormone-sensitive cancer, or if you haven't had recent bloodwork that would flag any concerning markers, that warrants a conversation with a physician first. IGF-1 LR3 is not appropriate for people with active cancer, in remission, or with elevated PSA without oncology clearance. What does your current CJC + ipamorelin protocol look like, and what's the primary goal — hypertrophy, recomposition, or both?

CONTINUE IN THE APP

Open PepperLedger to track your IGF-1 protocol →

Free to join. No credit card. Ask the Researcher about your IGF-1 LR3 protocol once you're in.

Free to join · No credit card · 23-day Pro trial included